Maqola mavzusi

Mualliflar

Haydarov A.B., Sobirova M.U.

Muassasa

Andijan State Medical Institute, Andijan, Uzbekistan

Annotatsiya

Background:Liver echinococcosis remains a significant global health issue, particularly in endemic regions where diagnostic and therapeutic challenges persist. The optimal dosing of albendazole in post-surgical chemotherapy continues to be debated, especially in patients with pre-existing hepatic dysfunction. Objective: This study aimed to evaluate the clinical and morphological rationale for adjusting albendazole dosages to improve safety and efficacy during postoperative chemotherapy for hepatic echinococcosis. Methods: An experimental study was performed using 32 naturally infected sheep and 371 patients diagnosed with liver echinococcosis. Albendazole was administered at varying dosages (5–20 mg/kg) across controlled experimental groups to assess its histopathological effects on parasitic cysts and hepatic tissue. Clinical patients were divided into a standard-dose group (10–15 mg/kg) and a dose-adjusted group (5–7 mg/kg) with concurrent monitoring of liver function biomarkers and recurrence rates. Results: Experimental data demonstrated that albendazole at 10–20 mg/kg induced a rapid proliferative-cellular response within two weeks, while the 5–7 mg/kg regimen achieved a similar effect within three to four weeks. Clinically, adjusting albendazole doses to 5–7 mg/kg in patients with diffuse hepatic disease reduced adverse effects from 52.7% to 18.3% and decreased recurrence from 11.9% to 2.6% (p<0.05). Conclusions: Morphological and clinical findings support the therapeutic adjustment of albendazole to 5–7 mg/kg in patients with compromised hepatic function. Dose correction not only preserves antiparasitic efficacy but significantly reduces hepatotoxicity and postoperative recurrence of liver echinococcosis

Kalit so'zlar

Liver echinococcosis, Albendazole, Chemotherapy adjustment, Surgical treatment, Hepatic safety, Re-currence prevention

Adabiyotlar